{"links":{"html":"https://www.erudio.com/reports/strategist-3-nct07218926","json":"https://www.erudio.com/reports/strategist-3-nct07218926.json","markdown":"https://www.erudio.com/reports/strategist-3-nct07218926.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"strategist-3-07218926"}},"request":"https://www.erudio.com/contact?report=strategist-3-07218926"},"offer":{"cited_commentary_sources":17,"verified_hcp_statements":84,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":5,"optional":true,"price_per_verified_person_usd":15,"price_usd":75,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"strategist-3-nct07218926"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=strategist-3-07218926","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/strategist-3-nct07218926","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T07:43:51.230571Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Progression-Free Survival (PFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":11,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":17,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":10,"title":"The comparison"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":15,"coverage":"discussed","id":"A1","source_count":7,"title":"Pre-switch referral, imatinib continuity and the risk of losing eligibility"},{"claim_count":16,"coverage":"discussed","id":"A2","source_count":2,"title":"Resistance profiling, mutation-guided selection and predictive uncertainty"},{"claim_count":15,"coverage":"discussed","id":"A3","source_count":3,"title":"Broad mutation coverage, competing regimens and resistance research"},{"claim_count":13,"coverage":"discussed","id":"A4","source_count":2,"title":"Progression assessment, systemic versus local treatment and the comparator pathway"},{"claim_count":16,"coverage":"discussed","id":"A5","source_count":9,"title":"Regional access, local co-management and preparation for shared decisions"},{"claim_count":10,"coverage":"discussed","id":"A6","source_count":7,"title":"Early evidence maturity and conditional future second-line options"}],"counts":{"cited_sources":18,"claims_by_expression_type":{"comparison":4,"experience":10,"interpretation":14,"opinion":35,"primary_context":3,"question":1,"restatement":11,"uncertainty":1,"unspecified":5},"claims_by_kind":{"protocol_statement":3,"source_observation":81},"clinician_statements":46,"evidence_units":51,"findings":9,"organisational_accounts":1,"people_cited":6,"people_identity_verified":5,"people_total":6,"screened_sources":22,"verified_claims":84},"findings_index":[{"id":"F1","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"media":1,"registry":1}},"title":"For mixed resistance, one speaker prefers an accessible combination over the randomized trial"},{"id":"F2","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":2,"views":11},"has_counterview":false,"limitations":3,"links":{"context":0,"support":18},"ma_question":true,"named_voices":2,"passages":11,"sources":8,"sources_by_kind":{"commentary":7,"registry":1}},"title":"Referral timing is portrayed as a treatment decision that can close access"},{"id":"F3","structure":{"claims":12,"claims_by_group":{"comparisons":2,"experience":3,"questions":1,"restated":1,"views":5},"has_counterview":true,"limitations":4,"links":{"context":0,"support":13},"ma_question":true,"named_voices":3,"passages":9,"sources":2,"sources_by_kind":{"media":2}},"title":"Molecular profiling is strongly supported, but a detected mutation is not a deterministic treatment rule"},{"id":"F4","structure":{"claims":14,"claims_by_group":{"comparisons":2,"experience":1,"questions":1,"restated":2,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":4,"passages":9,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Broad inhibition: an unseen-clone rationale, not demonstrated eradication or cure"},{"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":4},"has_counterview":false,"limitations":3,"links":{"context":1,"support":7},"ma_question":true,"named_voices":3,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Velzatinib enthusiasm rests on early activity and tolerability, pending randomized confirmation"},{"id":"F6","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":3,"views":5},"has_counterview":false,"limitations":4,"links":{"context":0,"support":11},"ma_question":true,"named_voices":2,"passages":5,"sources":2,"sources_by_kind":{"media":2}},"title":"Sunitinib's practical burden is part of the choice, not just an efficacy benchmark"},{"id":"F7","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":6},"has_counterview":false,"limitations":4,"links":{"context":0,"support":7},"ma_question":true,"named_voices":2,"passages":6,"sources":2,"sources_by_kind":{"media":2}},"title":"The post-imatinib decision also includes confirming progression and considering local treatment"},{"id":"F8","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":3,"sources":2,"sources_by_kind":{"media":2}},"title":"Additional second-line options remain a conditional forecast"},{"id":"F9","structure":{"claims":20,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":8,"views":10},"has_counterview":false,"limitations":4,"links":{"context":0,"support":23},"ma_question":true,"named_voices":4,"passages":14,"sources":10,"sources_by_kind":{"commentary":8,"media":1,"registry":1}},"title":"Regional coordination, full eligibility review and patient preparation are central to participation"}],"medical_affairs_question":"How can Medical Affairs distinguish molecular rationale, conditional access preferences and referral advice from demonstrated comparative benefit while preserving the tolerability and eligibility exceptions?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Mixed resistance: an option does not necessarily mean the preferred option"},{"id":"section-2","level":2,"title":"Referral before sunitinib: access and treatment continuity are linked"},{"id":"section-3","level":2,"title":"Profiling: strong support, exploratory evidence and imperfect prediction"},{"id":"section-4","level":2,"title":"Broad coverage: biological rationale versus an eradication hypothesis"},{"id":"section-5","level":2,"title":"Early velzatinib promise: phase 1 activity and safety, not phase 3 evidence"},{"id":"section-6","level":2,"title":"The comparator's burden: manageable treatment can still affect daily life"},{"id":"section-7","level":2,"title":"Work-up and local control can alter the framing of the systemic decision"},{"id":"section-8","level":2,"title":"Future options: conditional forecasts, not established approvals"},{"id":"section-9","level":2,"title":"Participation depends on geography, complete eligibility review and preparation"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F9","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS)"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F9","shared_claims":9}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":1},{"id":"F9","shared_claims":5}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":6}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F9","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T07:43:51.230571Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T07:56:49Z","record_hash":"dc8fcf414a7e7f759daaba4e092d2e1cd95518b8e1300d3c30a26e5a342133d1","release_hash":"529a216e8bdec1fa9c1601d9dde893b26abb09285825dd0a449bc461395c0a32","report_id":"erudio-nct07218926","run_id":"bb623d87-a374-490f-846d-f874bd1365ec","schema_version":"5.0","slug":"strategist-3-07218926","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"StrateGIST 3 asks whether velzatinib improves disease control and safety versus sunitinib after imatinib in metastatic or unresectable GIST. Commentary comes from X and LinkedIn posts and podcasts featuring medical oncologists and a hematology–oncology physician. Discussion centers on referral timing and whether randomized evidence will support early velzatinib enthusiasm. For mixed resistance, one medical oncologist’s conditional preference for an accessible combination over trial participation raises a competing treatment-choice question.","meta_description":"22 sources screened · 84 verified statements (46 from clinicians verified by NPI or staff page) from 18 sources · 9 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-3496f5b36d20ac5970a4","claim-f01575ccfd32fbf3dcf4"],"id":"F1","paraphrase":"A medical oncologist in a podcast discussion addressed the choice between StrateGIST 3 participation and an expanded-access combination for GIST with mixed resistance.","publication_caveats":["This is the podcast publication date; it does not establish when the discussion took place."],"source_channel":"podcast","source_date":"2026-03-20","title":"For mixed resistance, one speaker prefers an accessible combination over the randomized trial"},{"cited_claim_ids":["claim-4295338bd5735de5ec2b","claim-69fa11a2d44208284918","claim-52d073c965beb2746176"],"id":"F5","paraphrase":"A hematology–oncology physician’s podcast discussion addressed questions about early velzatinib activity and tolerability, and the randomized comparison with sunitinib.","publication_caveats":["This is the podcast publication date; it does not establish when the discussion took place."],"source_channel":"podcast","source_date":"2026-07-27","title":"Velzatinib enthusiasm rests on early activity and tolerability, pending randomized confirmation"}]},"publication":{"approved_at":"2026-10-31T07:56:49Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":22},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on early-line tolerability, activity and evidence limitations informing treatment selection after imatinib.","Not yet captured in this edition: a view on mutation coverage and combination alternatives for second-line treatment of advanced GIST.","Not yet captured in this edition: a view on timely trial referral and continuing imatinib before switching second-line treatment.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","48 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative HCP sample. Repeated posts and reposts should not be counted as independent views or consensus.","Some potentially relevant social posts and replies were not fully assessed, and some referral material had unresolved author attribution. Additional relevant views may be missing.","No exact-trial results publication was identified. No separate protocol or exact IDRX-42 regulatory label was available; comparative efficacy, comparative safety and regulatory outcomes cannot be concluded from this discussion.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Three speakers are each described in the source as involved in StrateGIST 3. Their favorable outreach is not treated as independent external validation.","Several clinical statements concern other studies, exploratory subgroups, practice experience or a presented case. Their relevance is to the post-imatinib decision, not to observed StrateGIST 3 outcomes.","The discussion of repeat molecular testing, specific combination choices and approval timing is incomplete; it should not be read as a comprehensive account of those recommendations or forecasts.","Publication and post dates establish when material appeared, not necessarily when a session occurred, results were presented or an opinion changed."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":4,"other":0,"podcast":2,"publication":0,"registry":1,"regulatory":0,"x_thread":11,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":17,"methods":1},"count":18,"evidence_window":{"end":"2026-10-07","start":"2026-03-20"},"retrieval_snapshot":"2026-10-31T06:37:02.764638Z","timeline":[{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W19"},{"count":3,"week":"2026-W22"},{"count":2,"week":"2026-W24"},{"count":2,"week":"2026-W28"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":4,"week":"2026-W40"},{"count":1,"week":"2026-W41"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT07218926:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07218926:context","quote_policy":"short_quote_link_out"},{"id":"openfda:43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c:20260220","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7457492361997111296","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7471252169288073216","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7492922123183751172","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7511240836882395137","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7511960428973903872","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:731c16","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:da55ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1983471425290908091:2f1b932f-c579-43c9-830f-fbb145d40bcd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049911339100065825:de650583-20e0-4386-93ab-f051ad5dd290","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052025597568651462:58bf20bd-8193-4a1d-b2d2-a2eac1e41801","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052040299786981804:1f6c8c2a-f57b-4d9a-86bf-4feace72a60b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052040483484971231:a4557862-45cc-44de-bcf6-b5c167af8c64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060824147752616339:fdf699f7-0b55-43c6-9fd9-6cfc472ca268","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060827586368823680:b5e87a31-4169-4e0c-a44c-ff8b5b8038b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060827849175511217:f31b3398-1060-47e1-89cf-28e077f17169","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065281137841205253:b0613db6-53b9-461b-9d69-f7b189d0179f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074639322699956448:6148d84f-9fa5-4289-913c-35e24722556b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074640114479669611:78b5bca8-b316-4d7c-af31-752d375336af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092624439561138523:683b0e80-445a-4a16-bbd2-b00f1fae184b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095305029624177059:4aa147af-42a1-4a8d-a5ac-c84e1721ef26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105477182667493644:05ce5171-5047-44b2-984f-c9573e97f0e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106201320549990772:cc26bd68-9308-4287-a006-acdd98131732","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":5,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":22},"count":22,"evidence_window":{"end":"2026-10-07","start":"2025-10-29"},"retrieval_snapshot":"2026-10-31T06:37:02.764638Z","timeline":[{"count":1,"week":"2025-W44"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W18"},{"count":4,"week":"2026-W19"},{"count":3,"week":"2026-W22"},{"count":2,"week":"2026-W24"},{"count":2,"week":"2026-W28"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W36"},{"count":4,"week":"2026-W40"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: idrx-42","status":"unmapped"},{"brand_names":["Sutent"],"label":"sunitinib","slug":"sunitinib"}],"indications":[{"reason":"Unmapped registry condition: Gastrointestinal Neoplasms","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"StrateGIST 3","aliases":["StrateGIST 3","A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)"],"brief_title":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Gastrointestinal Neoplasms"],"display_condition":"metastatic and/or unresectable gastrointestinal stromal tumors after imatinib","display_interventions":[["velzatinib (IDRX-42)"]],"enrollment":{"count":450,"type":"ESTIMATED"},"interventions":[{"name":"IDRX-42","synonyms":["velzatinib - subject to USAN approval"],"type":"DRUG"},{"name":"Sunitinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07218926","official_title":"A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-05-30","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.","measure":"Progression-Free Survival (PFS)","timeFrame":"Up to approximately 130 weeks"}],"registered_date":{"date":"2025-10-21","type":"ACTUAL"},"registry_last_updated":"2026-10-05","registry_url":"https://clinicaltrials.gov/study/NCT07218926","short_name":"StrateGIST 3","short_name_basis":"canonical_name","sponsor":"GlaxoSmithKline","start_date":{"date":"2025-12-03","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"300383","type":"sponsor_study_id"},{"id":"2025-522229-37-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}